• Revenue up 13.1% to $1.85 billion
• EBITDA up 10.5% to $47.5 million
• NPAT up 85.9% to $13.2 million
• Integration of CH2 and Oborne Health on track

Paragon Care has reported a strong set of financial results for the first half of FY25. Revenue increased by 13.1% to $1.85 billion, EBITDA grew by 10.5% to $47.5 million, and net profit after tax was up 85.9% to $13.2 million. The company's performance was driven by solid growth in its Pharmacy, Diagnostics and Complementary Medicines divisions, as well as strong growth in its Asian operations. However, the Capital & Service and Surgical Specialties divisions faced some challenges during the period. Paragon Care continues to execute on its integration plan following the merger with CH2 Holdings and Oborne Health Supplies, with the new organisational structure now in place and progress being made on synergy targets. The company remains focused on operational efficiency, cross-selling its expanded product range, and pursuing strategic acquisition opportunities to drive further growth.

Paragon Care is on track to achieve annual synergies of $5 million in FY25 and $12 million in FY26 from the integration of CH2 and Oborne Health.

Paragon Care will continue to execute on its integration plan, increase cross-selling of its expanded product range, focus on operational efficiency and cost rationalisation, and actively review its customer, product and agency partner pipeline to drive organic growth. The company also has an acquisition pipeline in place to pursue additional growth opportunities.